RenovoRx, Inc. (RNXT)
1.28
-0.05
(-3.76%)
USD |
NASDAQ |
Oct 09, 16:00
1.32
+0.04
(+3.12%)
After-Hours: 20:00
RenovoRx Cash from Operations (Quarterly) : -2.867M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.867M |
| March 31, 2026 | -3.709M |
| December 31, 2025 | -3.02M |
| September 30, 2025 | -2.27M |
| June 30, 2025 | -2.302M |
| March 31, 2025 | -3.381M |
| December 31, 2024 | -2.43M |
| September 30, 2024 | -2.194M |
| June 30, 2024 | -2.297M |
| March 31, 2024 | -2.204M |
| December 31, 2023 | -2.053M |
| September 30, 2023 | -2.728M |
| June 30, 2023 | -2.771M |
| Date | Value |
|---|---|
| March 31, 2023 | -2.706M |
| December 31, 2022 | -1.681M |
| September 30, 2022 | -2.672M |
| June 30, 2022 | -2.361M |
| March 31, 2022 | -2.097M |
| December 31, 2021 | -2.558M |
| September 30, 2021 | -1.119M |
| June 30, 2021 | -1.247M |
| March 31, 2021 | -0.992M |
| December 31, 2020 | |
| September 30, 2020 | -0.691M |
| June 30, 2020 | -0.814M |
| March 31, 2020 | -1.053M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Enanta Pharmaceuticals, Inc. | -9.972M |
| Travere Therapeutics, Inc. | 58.07M |
| REGENXBIO, Inc. | -62.24M |
| Krystal Biotech, Inc. | 74.79M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.071M |
| Cash from Financing (Quarterly) | 0.055M |
| Free Cash Flow | -11.94M |
| Free Cash Flow Per Share (Quarterly) | -0.0621 |
| Free Cash Flow to Equity (Quarterly) | -3.142M |
| Free Cash Flow to Firm (Quarterly) | -2.938M |
| Free Cash Flow Yield | -23.52% |